{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:37:41Z","timestamp":1791607061324,"version":"4.3.4"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013207","name":"Reckitt Benckiser Pharmaceuticals","doi-asserted-by":"publisher","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100013207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2022,11,18]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background\/aims<\/jats:title>\n                  <jats:p>Investigation of gastro-oesophageal reflux disease is usually performed off proton pump inhibitors (PPIs). This can exacerbate symptoms, potentially impacting investigation accuracy if patients circumvent the preinvestigation instructions. There are no standard recommendations on how to manage PPI withdrawal. We aimed to assess the impact of structured alginate use on symptom burden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were already established on \u22654 weeks of PPI therapy and being referred for manometry and 24-hour pH\/impedance testing. Preinvestigation instructions involved stopping PPIs and H2 receptor antagonists for 1 week, but antacids and alginates were allowed until the night before. Participants were randomised to follow these standard instructions (control group), or the same instructions with the provision of Gaviscon Advance to be taken four times daily (treatment group). The primary outcome assessed change in Gastro-Oesophageal Reflux Disease Health-Related Quality of Life Score.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key results<\/jats:title>\n                  <jats:p>Data for 48 patients were available for primary outcome assessment. While patients in the control group had a significant increase in symptoms (median difference 6.5, 95% CI (1 to 7), p=0.04), no change occurred in the treatment arm (median difference -1.5, 95% CI (-2, 3.5), p=0.54). There were no serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Structured alginate use prevents symptom exacerbation during preinvestigation PPI wash-out. These findings are limited to the 1-week wash-out period but can benefit thousands of patients undergoing investigation for gastro-oesophageal reflux each year. Further research is required to assess this effect in other settings, such as sustained PPI deprescription. The trial was funded by Reckitt Benckiser.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>EudraCT registration 2019-004561-41<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2022-001026","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T10:43:13Z","timestamp":1673347393000},"page":"e001026","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Randomised clinical trial: the use of alginates during preinvestigation proton pump inhibitor wash-out and their impact on compliance and symptom burden"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7774-310X","authenticated-orcid":false,"given":"Andres","family":"Vales","sequence":"first","affiliation":[{"name":"The Functional Gut Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"Coyle","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Plc, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Plehhova","sequence":"additional","affiliation":[{"name":"Reckitt Benckiser Plc, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hobson","sequence":"additional","affiliation":[{"name":"The Functional Gut Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Woodland","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"2025073013070090000_10.1.e001026.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304269"},{"key":"2025073013070090000_10.1.e001026.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0164-8"},{"key":"2025073013070090000_10.1.e001026.3","unstructured":"NHS Digital . Prescription cost analysis, 2018. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/prescription-cost-analysis"},{"key":"2025073013070090000_10.1.e001026.4","unstructured":"Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management . National Institute for health and care excellence: clinical guidelines. London, 2019."},{"key":"2025073013070090000_10.1.e001026.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-7-200404060-00011"},{"key":"2025073013070090000_10.1.e001026.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01593.x"},{"key":"2025073013070090000_10.1.e001026.7","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13735","article-title":"Exacerbation of gastroesophageal reflux symptoms after discontinuation of proton pump inhibitors is not associated with increased esophageal acid exposure","volume":"32","author":"Hoshikawa","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"2025073013070090000_10.1.e001026.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.058"},{"key":"2025073013070090000_10.1.e001026.9","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.81"},{"key":"2025073013070090000_10.1.e001026.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02289.x"},{"key":"2025073013070090000_10.1.e001026.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.046"},{"key":"2025073013070090000_10.1.e001026.12","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00424.2014"},{"key":"2025073013070090000_10.1.e001026.13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/apt.15884","article-title":"Duration of adhesion of swallowed alginates to distal oesophageal mucosa: implications for topical therapy of oesophageal diseases","volume":"52","author":"Sonmez","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013070090000_10.1.e001026.14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/apt.12640","article-title":"Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease","volume":"39","author":"Thomas","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013070090000_10.1.e001026.15","doi-asserted-by":"publisher","DOI":"10.1111\/dote.12495"},{"key":"2025073013070090000_10.1.e001026.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30162.x"},{"key":"2025073013070090000_10.1.e001026.17","first-page":"141","article-title":"Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice","volume":"20","author":"Murie","year":"2012","journal-title":"Qual Prim Care"},{"key":"2025073013070090000_10.1.e001026.18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0018578717747192","article-title":"Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution","volume":"53","author":"Wahking","year":"2018","journal-title":"Hosp Pharm"},{"key":"2025073013070090000_10.1.e001026.19","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen19X101651"},{"key":"2025073013070090000_10.1.e001026.20","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13067"},{"key":"2025073013070090000_10.1.e001026.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2007.00658.x"},{"key":"2025073013070090000_10.1.e001026.22","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-6-12","article-title":"Reliability and validity of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study","volume":"6","author":"Kulich","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"2025073013070090000_10.1.e001026.23","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12299"},{"key":"2025073013070090000_10.1.e001026.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314722"},{"key":"2025073013070090000_10.1.e001026.25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.035"},{"key":"2025073013070090000_10.1.e001026.26","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13567"},{"key":"2025073013070090000_10.1.e001026.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00684.x"},{"key":"2025073013070090000_10.1.e001026.28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-7-199810010-00007"},{"key":"2025073013070090000_10.1.e001026.29","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12246"},{"key":"2025073013070090000_10.1.e001026.30","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.051821"},{"key":"2025073013070090000_10.1.e001026.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05532.x"},{"key":"2025073013070090000_10.1.e001026.32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327326"},{"key":"2025073013070090000_10.1.e001026.33","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.4.464"},{"key":"2025073013070090000_10.1.e001026.34","doi-asserted-by":"crossref","DOI":"10.1136\/flgastro-2020-101538","article-title":"National census of UK endoscopy services in 2019","volume":"12","author":"Ravindran","year":"2021","journal-title":"Frontline Gastroenterol"},{"key":"2025073013070090000_10.1.e001026.35","unstructured":"MHRA . Drug alert: recalls for 13 over-the-counter ranitidine medicines, 2019. Available: https:\/\/www.gov.uk\/government\/news\/mhra-drug-alert-recalls-for-13-over-the-counter-ranitidine-medicines"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2022-001026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:07:10Z","timestamp":1753906030000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2022-001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,10]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/bmjgast-2022-001026"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2022-001026","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}